Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flutamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CES2 | O00748 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | AADAC | P22760 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flutamide SCHEMBL1461845 | 1.00 | AR (1.00) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL29349783 | 1.00 | AR (1.00) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL28162762 | 0.99 | AR (0.97) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL21753660 | 0.99 | AR (0.97) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL679388 | 0.96 | AR (0.93) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL7104567 | 0.95 | AR (0.90) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL1028216 | 0.93 | AR (0.86) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| SCHEMBL11512367 | 0.91 | AR (0.83) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| SCHEMBL19117466 | 0.90 | AR (0.81) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| SCHEMBL11512254 | 0.90 | AR (0.81) | ARCYP3A4CES2ABCB11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 105522 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4746898-A2 | IDENTIFICATION OF SEQUENCE VARIANTS OF THE ERVMER34-1 SEQUENCE FAMILY AND USE IN ANTI-CANCER THERAPIES | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4467200-B1 | EZH2 INHIBITION THERAPIES FOR THE TREATMENT OF ANDROGEN RECEPTOR MUTATED PROSTATE CANCERS | CONSTELLATION PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-20260137678-A1 | METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING XPO1 INHIBITORS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-21 | — | — | US | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-4745155-A1 | POWDER CONTAINING PARTICLES OF GELATIN DERIVATIVE AND APPLICATION OF SAME IN MEDICAL TREATMENT | National Institute for Materials Science (JP) | 2026-05-20 | — | — | EP | claimed |
| CN-122070133-A | Pharmaceutical compositions containing androgen receptor inhibitors/antagonists, methods and uses | 苏州开拓药业股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-4598072-A | Combinations of an aromatase-inhibitor and an antiandrogen for prophylaxis and/or treatment of benign prostatic hyperplasia | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-07-01 | — | — | US | claimed |
| WO-1986001105-A1 | PHARMACEUTICAL COMPOSITION FOR COMBINATION THERAPY OF HORMONE DEPENDENT CANCERS | LABRIE FERNAND (CA) | 1986-02-27 | — | — | WO | claimed |
| US-4474813-A | PROSTATIC CARCINOMA | SCHERING CORPORATION (US) | 1984-10-02 | — | — | US | claimed |
| US-4472382-A | Treatment method | ROUSSEL UCLAF (FR) | 1984-09-18 | — | — | US | claimed |
| US-4329364-A | Antiandrogenic agents and methods for the treatment of androgen dependent disease states | SCHERING CORPORATION (US) | 1982-05-11 | — | — | US | claimed |
| US-4302599-A | Process for nitrating anilides | SCHERING CORPORATION (US) | 1981-11-24 | — | — | US | claimed |
| US-4161540-A | SUBSTITUTED ANILIDE | SCHERING CORPORATION (US) | 1979-07-17 | — | — | US | claimed |
| US-4139638-A | NITRO OR HALOGEN SUBSTITUTED ANILIDES, ANTIANDROGENS, ACNE, CANCER | SCHERING CORPORATION (US) | 1979-02-13 | — | — | US | claimed |
| US-4039684-A | 4-NITRO-3-TRIFLUOROMETHYL-ISOBUTYRANILIDE OR CORRESPONDING 2-HYDROXY- COMPOUND | SCHERING CORPORATION (US) | 1977-08-02 | — | — | US | claimed |
| US-3995060-A | SUBSTITUTED ANILIDES | SCHERING CORPORATION (US) | 1976-11-30 | — | — | US | claimed |